Roche says Phase II trial shows enicepatide cuts HbA1c 2.65% in type 2 diabetes patients at 48 weeks

PUBT · 1d ago
Roche says Phase II trial shows enicepatide cuts HbA1c 2.65% in type 2 diabetes patients at 48 weeks
  • Roche reported positive topline Phase II results for enicepatide, a once-weekly dual GLP-1/GIP agonist, in type 2 diabetes.
  • The trial showed clinically meaningful improvements in blood sugar control, with many patients reaching diabetes targets or normal-range glucose levels.
  • Participants also recorded sustained weight loss over the study period, supporting enicepatide’s positioning in cardiometabolic disease.
  • Safety broadly matched the incretin class, with mostly mild-to-moderate gastrointestinal effects and low treatment discontinuations.
  • Roche is running two Phase III weight-management studies, with Phase III diabetes and cardiovascular outcomes programs planned for 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220100OMX_____CNEWS_EN_GNW1001273913_en) on September 22, 2026, and is solely responsible for the information contained therein.